Publication date: 1 November 2026 Source: Drug and Alcohol Dependence, Volume 288 Author(s): Lydia N. Drumright, Kanna Hayashi, Shruti H. Mehta, Mai T. Pho, Kora DeBeck, Heidi M. Crane, Becky L. Genberg, Hannah Cooper, Sonia Napravnik, William Zule, Kenneth H. Mayer, Thomas J. Stopka, Laura Bamford, William C. Miller, George Yendewa, Vivan F. Go, Greer Burkholder, P. Todd Korthuis, Katerina Christopoulos, David W. Seal
Higher prevalence of non-fatal overdose with opioid and stimulant use compared to use of opioids alone. // Drug and Alcohol Dependence. – URL: https://www.sciencedirect.com/science/article/pii/S0376871626003431?dgcid=rss_sd_all
Higher prevalence of non-fatal overdose with opioid and stimulant use compared to use of opioids alone. Drug and Alcohol Dependence. https://www.sciencedirect.com/science/article/pii/S0376871626003431?dgcid=rss_sd_all
“Higher prevalence of non-fatal overdose with opioid and stimulant use compared to use of opioids alone.” Drug and Alcohol Dependence.
@article{article93695,
title = {Higher prevalence of non-fatal overdose with opioid and stimulant use compared to use of opioids alone},
journal = {Drug and Alcohol Dependence},
url = {https://www.sciencedirect.com/science/article/pii/S0376871626003431?dgcid=rss_sd_all}
}
Acta Pharmacologica Sinica, Published online: 16 November 2026; doi:10.1038/s41401-026-01953-z IRAK4 inhibitor DW18134 ameliorates diffuse large B-cell lymphoma in combination with ibrutinib and overcomes acquired resistance to ibrutinib
Acta Pharmacologica Sinica, Published online: 16 November 2026; doi:10.1038/s41401-026-01958-8 Artificial intelligence aids multi-omics data integration in cancer drug discovery and development: from targets to drug synergy
Nature Reviews Drug Discovery, Published online: 13 November 2026; doi:10.1038/d41573-026-00179-2 The NIH’s P. J. Brooks discusses the challenges and opportunities ahead for gene therapies and gene editing for diseases of no commercial interest.
Nature Reviews Drug Discovery, Published online: 13 November 2026; doi:10.1038/d41573-026-00181-8 Merck and Moderna’s intismeran autogene succeeded in a landmark melanoma trial, but the oncology community still has more questions than...